KLRS
Kalaris Therapeutics Inc NASDAQ Listed Jul 30, 2020$4.08
+5.15%
vs $3.88
Mkt Cap $89.1M
52w Low $2.36
18.1% of range
52w High $11.88
50d MA $4.22
200d MA $6.51
P/E (TTM)
—
EV/EBITDA
—
P/B
0.8x
Debt/Equity
0.0x
ROE
-55.1%
P/FCF
-1.4x
RSI (14)
63.00
ATR (14)
$0.31
Beta
0.18
50d MA
$4.22
200d MA
$6.51
Avg Volume
457.2K
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
139 Main Street, Suite 500 · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | TNS | -0.49 | -0.48 | +3.0% | 3.97 | +4.5% | -0.8% | -1.5% | — | — | — | — |
| May 12, 2026 | TNS | -0.52 | -0.46 | +11.5% | 4.79 | -2.7% | +0.8% | +8.1% | -6.1% | -3.3% | -0.8% | — |
| Mar 17, 2026 | TNS | -0.56 | -0.44 | +21.4% | 8.52 | -0.2% | -11.6% | -9.6% | -3.5% | -1.1% | -4.6% | — |
| Nov 12, 2025 | TNS | -0.66 | -0.64 | +3.0% | 4.96 | -1.8% | +7.5% | +2.4% | -0.7% | +19.0% | +3.6% | — |
| Aug 13, 2025 | TNS | -0.51 | -0.61 | -19.6% | 2.28 | +0.0% | -0.4% | +8.4% | +1.6% | +2.8% | +0.0% | — |
| May 14, 2025 | TNS | -0.78 | -2.52 | -223.1% | 3.38 | -4.7% | +4.7% | -1.7% | -6.6% | +2.5% | -10.5% | — |
| Mar 7, 2025 | TNS | -2.76 | -3.64 | -31.8% | 9.87 | -1.8% | -6.8% | +3.2% | +1.9% | -5.7% | +5.8% | — |
| Nov 12, 2024 | TNS | -0.14 | -0.04 | +71.4% | 286.45 | -0.3% | +4.0% | -1.8% | +2.9% | +1.8% | -3.4% | — |
| Jun 30, 2024 | TNS | -2.37 | -1.13 | +52.2% | — | — | — | — | — | — | — | — |
| May 13, 2024 | TNS | -3.62 | -5.98 | -65.4% | 396.80 | -3.3% | +2.9% | -2.9% | +0.2% | +3.2% | -0.8% | — |
| Mar 31, 2024 | AMC | -3.62 | -0.68 | +81.1% | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | TNS | -9.84 | -0.70 | +92.9% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | TNS | — | -8.94 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -11.00 | — | 1798.60 | -0.3% | -4.7% | -1.5% | -3.8% | +4.6% | +1.6% | — |
| Mar 31, 2023 | AMC | — | -10.15 | — | 2084.26 | -0.3% | -1.0% | -2.6% | -3.2% | +3.3% | -0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 | TD Cowen | Initiates | Buy | — | $4.33 | $4.54 | +4.8% | -1.4% | +2.3% | +4.1% | +3.7% | -6.8% |
| May 14 | Wedbush | Initiates | Outperform | $17 | $4.83 | $4.90 | +1.4% | +8.1% | -6.1% | -3.3% | -0.8% | +2.8% |
No insider trades available.
8-K
Kalaris Therapeutics Inc -- 8-K Filing
Aug 11
8-K
Kalaris Therapeutics Inc -- 8-K Filing
Kalaris Therapeutics appointed a new executive who executed standard restrictive covenants including non-compete, non-solicitation, and intellectual property protection agreements typical of senior employment arrangements.
Jul 20
8-K · 7.01
! Medium
Kalaris Therapeutics Inc -- 8-K 7.01: Regulation FD Disclosure
Jul 17
8-K
Kalaris Therapeutics Inc -- 8-K Filing
May 12
8-K
Unknown — 8-K Filing
A new executive compensation package signals leadership continuity, but the $540,000 salary and 40% bonus structure indicate moderate executive costs that shouldn't meaningfully impact shareholder value.
Apr 15
8-K
Unknown — 8-K Filing
Executive compensation arrangements for Hagen's appointment were disclosed under regulatory requirements, which investors should monitor for potential conflicts of interest or excessive pay packages affecting shareholder value.
Apr 10
8-K
Unknown — 8-K Filing
Kalaris achieved significant clinical or operational milestones in 2025 that could accelerate its path to commercialization, potentially justifying higher valuations if upcoming trial results prove efficacy in retinal disease treatments.
Mar 17
8-K
Kalaris Therapeutics, Inc. -- 8-K Filing
Kalaris Therapeutics disclosed forward-looking statements regarding its TH103 Phase 1b/2 trial data reporting timeline and planned Phase 3 clinical development initiation.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Samsara Biocapital, Llc | 12,948,081 | $109M | Added | Dec 2025 |
| 2 | Rtw Investments, Lp | 1,300,000 | $8M | — | Mar 2026 |
| 3 | Alyeska Investment Group, L.p. | 572,687 | $3M | Added | Mar 2026 |
| 4 | Propel Bio Management, Llc | 295,771 | $2M | Added | Mar 2026 |
| 5 | Raymond James Financial Inc | 118,887 | $686K | Added | Mar 2026 |
| 6 | Woodline Partners Lp | 100,000 | $577K | — | Mar 2026 |
| 7 | Adar1 Capital Management, Llc | 100,000 | $577K | New | Mar 2026 |
| 8 | Morgan Stanley | 55,896 | $472K | Added | Dec 2025 |
| 9 | Marshall Wace, Llp | 67,879 | $392K | Reduced | Mar 2026 |
| 10 | Renaissance Technologies Llc | 66,151 | $382K | Reduced | Mar 2026 |
| 11 | Millennium Management | 59,534 | $344K | New | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 52,684 | $304K | Added | Mar 2026 |
| 13 | Jane Street Group, Llc | 33,114 | $279K | New | Dec 2025 |
| 14 | Rbf Capital, Llc | 34,782 | $201K | — | Mar 2026 |
| 15 | Two Sigma Investments, Lp | 30,650 | $177K | Added | Mar 2026 |
| 16 | Stonepine Capital Management, Llc | 20,400 | $118K | New | Mar 2026 |
| 17 | Johnson Financial Group, Inc. | 10,000 | $84K | — | Dec 2025 |
| 18 | Northern Trust Corp | 14,449 | $83K | Added | Mar 2026 |
| 19 | Hrt Financial Lp | 11,617 | $67K | New | Mar 2026 |
| 20 | Qube Research & Technologies Ltd | 11,103 | $64K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 33,978 | $355K | Feb 2026 |
| 2 | Fidelity Nasdaq Composite Index Fund | 16,829 | $176K | Feb 2026 |
| 3 | Ultra-Small Company Market Fund | 22,500 | $130K | Mar 2026 |
| 4 | Fidelity Total Market Index Fund | 9,885 | $52K | May 2026 |
| 5 | Fidelity Series Total Market Index Fund | 9,575 | $50K | May 2026 |
| 6 | iShares Micro-Cap ETF | 8,699 | $50K | Mar 2026 |
| 7 | LVIP Dimensional U.S. Core Equity 2 Fund | 135 | $549 | Jun 2026 |
| 8 | Guggenheim Active Allocation Fund | 7 | $73 | Feb 2026 |
Valuation
Market Cap
$89.1M
Enterprise Value
-$55.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
0.79x
P/S
—
P/FCF
-1.44x
EV/EBITDA
—
Shares Out
15.3M
Financials (TTM)
Revenue
$0
Net Income
-$44.3M
EBITDA
-$45.1M
Free Cash Flow
-$43.2M
Op Cash Flow
-$43.0M
EPS Basic
$-2.85
EPS Diluted
$-2.02
EPS Forward
$-2.19
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$121.7M
Total Liab.
$42.9M
Total Equity
$78.8M
Cash
$118.0M
LT Debt
$0
Book Value/Sh
$5.16
Debt/Equity
0.02x
Current Ratio
12.23
Quick Ratio
12.23
Returns & Growth
ROE
-55.1%
ROA
-35.7%
ROIC
-41.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+75.7%
Price Returns
2W
+16.2%
1M
-15.4%
3M
-16.7%
6M
-52.8%
12M
+65.9%
Technicals
52W High
$11.88
52W Low
$2.36
50d MA
$4.22
200d MA
$6.51
RSI (14)
63.00
ATR (14)
$0.31
Beta
0.18
Avg Volume
457K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$18.67
High
$23.00
Low
$14.00
Median
$19.00
Data updated apr 25, 2026 5:36pm
· Source: financialmodelingprep.com